Logo Logo Logo Logo Logo
  • Qui sommes-nous ?
    • Dirigeants
    • Notre équipe
    • Carrières
    • Développement commercial
  • Domaines de diagnostic
    • COVID-19
    • Innovation intelligente
  • Produits
    • Solutions de flux de travail
  • Actualités
  • Investisseurs
    • Calendrier institutionnel
    • Rapports financiers
    • Dirigeants
    • Assemblées générales
    • Autres informations réglementées
    • Contacts
    • AIM Rule 26 information
    • Gouvernement d’entreprise
  • Contact
  • Français
    • Anglais
  • Qui sommes-nous ?
    • Dirigeants
    • Notre équipe
    • Carrières
    • Développement commercial
  • Domaines de diagnostic
    • COVID-19
    • Innovation intelligente
  • Produits
    • Solutions de flux de travail
  • Actualités
  • Investisseurs
    • Calendrier institutionnel
    • Rapports financiers
    • Dirigeants
    • Assemblées générales
    • Autres informations réglementées
    • Contacts
    • AIM Rule 26 information
    • Gouvernement d’entreprise
  • Contact
  • Français
    • Anglais
Search:

21 Déc Novacyt launches two new CE-IVD Marked molecular diagnostic kits

Posted at 10:00h in Blog, genesig qPCR Detection Kits, News

First of an expanding menu of tests for monitoring post-transplantation and immunosuppressed patients Paris, France and Camberley, UK – 21 December 2018: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist...

Read More

06 Déc Completion of substantial q16 molecular diagnostics order

Posted at 14:03h in Blog, News

Completion of substantial q16 molecular diagnostics order expands clinical diagnostic reach in fast growing Chinese market Paris, France and Camberley, UK – 6th December 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM:...

Read More

06 Déc INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL

Posted at 10:27h in Board, Novacyt Group, Products

Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers https://novacyt.com/wp-content/uploads/2018/12/NOVACYT_CP_Droits-de-vote_2018-Dec.pdf ...

Read More

06 Nov INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL

Posted at 10:25h in Board, Novacyt Group, Products

Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers https://novacyt.com/wp-content/uploads/2018/11/NOVACYT_CP_Droits-de-vote_2018-Nov.pdf ...

Read More

03 Oct INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL

Posted at 10:22h in Board, Novacyt Group, Products

Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers https://novacyt.com/wp-content/uploads/2018/10/NOVACYT_CP_Droits-de-vote_2018-Oct.pdf ...

Read More

13 Sep NOVACYT PARTNERS WITH APPLIED MICROARRAYS IN ASSAY DESIGN

Posted at 13:22h in Blog, News

US partnership to facilitate the design and optimisation for customised microarray assays Paris, France and Camberley, UK – 13 September 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist...

Read More

05 Sep New research shows a fifth of samples contain unspecified animals’ DNA

Posted at 12:44h in Blog, Meat speciation

New research* released today shows that little progress may have been made since the last food scandal in 2013. Out of 665 results from England, Wales and Northern Ireland collected...

Read More

28 Juin Novacyt Announces Acquisition of Infectious Disease Business from Omega Diagnostics

Posted at 09:10h in Blog, News

Accelerating profitability by expanding the Lab21 business with complimentary products Paris, France and Camberley, UK – 28th June 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical...

Read More

15 Mai Primerdesign’s quality control: The what’s and why’s of ISO certification

Posted at 10:30h in Behind the scenes, Blog, Quality Control

Quality is paramount to Primerdesign’s success and reputation. It is critical that customers are confident in the quality and performance of our products. By promoting a culture of improvement, accountability...

Read More

23 Avr An innovative approach to qPCR multiplexing: A Q+A with Sara Arocas-Torrecillas

Posted at 10:09h in Behind the scenes, Blog, genesig qPCR Detection Kits

Primerdesign is proud to present three brand new real-time PCR product ranges to our portfolio. Firstly, genesigMYPLEX qPCR Kit STD is a personalised approach to multiplex assays. You have full...

Read More
  • 1
  • 2

Qui sommes-nous?


Novacyt est une société mondiale leader dans le domaine du diagnostic. Nous protégeons les personnes et la société dans la lutte contre les maladies infectieuses.

Société


York House, School Lane, Chandlers Ford, Eastleigh, SO53 4DG

Novacyt UK Holdings - 12031776
Novacyt SA - 491062527

Rapports financiers


Présentation Investisseurs Septembre 2022

© 2022 Novacyt | Politique de confidentialité | Propriété intellectuelle | Conditions d’utilisation

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Enregistrer & appliquer